Cipla Ltd. benchmarking: Perfomance to industry peers

Financial

	Cipla	Torrent Pharma	Dr. Reddy's Lab
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	282.0 .	172.0 .	362.0 .
Number of ANDA's Approved By USFDA	217.0 .	132.0 .	292.0 .
Domestic Sales Growth - YoY	6.8 %	12.3 %	9.1 %
US DMF Filings	2472.0 .	n/a	n/a
R&D as a % of Total Sales	6.2 %	5.0 %	7.3 %
Financials
5 yr Average ROE	13.9 %	20.79 %	15.68 %
5yr average Equity Multiplier	1.25	2.16	1.41
5yr Average Asset Turnover Ratio	0.78	0.69	0.74
5yr Avg Net Profit Margin	14.31 %	13.95 %	15.18 %
Price to Book	4.04	15.8	3.26
P/E	23.36	59.91	19.26
5yr Avg Cash Conversion Cycle	-4.31 Days	-186.79 Days	74.48 Days
Inventory Days	57.83 Days	54.98 Days	76.14 Days
Days Receivable	50.64 Days	40.18 Days	95.44 Days
Days Payable	105.99 Days	298.32 Days	102.6 Days
5yr Average Interest Coverage Ratio	53.73	7.38	35.66
5yr Avg ROCE	19.36 %	25.78 %	21.82 %
5yr Avg Operating Profit Margin	23.02 %	30.49 %	23.61 %
5 yr average Debt to Equity	0.03	0.66	0.12
5yr CAGR Net Profit	17.0 %	8.83 %	23.71 %
5yr Average Return on Assets	11.19 %	9.73 %	11.24 %
Shareholdings
Promoter Holding	29.19 %	68.31 %	26.64 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-4.42 %	-2.94 %	-0.07 %
Change in Mutual Fund Holding (3 Yrs)	7.05 %	-2.83 %	-0.6 %

Business

	Cipla	Torrent Pharma	Dr. Reddy's Lab
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 93.68 New ventures 6.32 US Formulations 0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0 Proprietary Products 0 Global Generics 0 0	Product Wise Break-Up Domestic Formulations 42.15 Proprietary Products 0 US Formulations 20.71 Pharmaceutical 0 New ventures 0 Contract Manufacturing 6.15 Global Generics 0 Germany 13.15 Brazil 8.98 0 Others 8.86	Product Wise Break-Up Domestic formulations 0 Proprietary 1.88 US Formulations 0 Pharmaceutical 0 New ventures 0 Contract Manf. 0 Formulations 86.8 Germany/Europe 0 Brazil/Latam 0 Pharmaceutical 11.32
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Respiratory Systems 36.4 Anti-Infective 13.8 Cardiac Science 11.8 Gastro Intestinal 5.5 Anti - Diabetes 5.5 Urology 5.1 Central Nervous System (CNS) 4.5 Pain Management 4.3 Derma 3.5 Ophthalmology 2.6 Antivirals 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Oncology 0 Others 7.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 44.0 North America 28.0 SAGA 13.0 Europe 12.0 Global API 1.0 Rest of the World 0 Emerging Markets 0 Germany 0 USA 0 Brazil 0 Russia 0 Others 2.0	Location Wise Break-Up USA 9.69 North America 0 Germany 9.69 Emerging Markets 0 Brazil 6.86 Europe 0 SAGA 0 Rest of the World 0 Global API 0 India 56.99 Russia 0 Others 16.77	Location Wise Break-Up USA 48.56 North America 0 Germany 0 Emerging Markets 0 Brazil 0 Europe 0 SAGA 0 Rest of the World 0 Global API 0 India 17.36 Russia 7.99 Others 26.09
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 96.82 New Ventures 3.18 Proprietary Products 0 0 Global Generics 0	-	Operating Profit Break-Up New Ventures 0 Pharmaceuticals 0 Global Generics 94.76 Proprietary Products 3.0 Pharmaceutical Services and Active Ingredients 2.24
Asset Break-Up	Asset Break-Up India 49.7 USA 28.99 South Africa 18.03 United States 0 Switzerland 0 Others 3.28	Asset Break-Up USA 0.46 United States 0 South Africa 0 Switzerland 0 India 94.39 Others 5.15	Asset Break-Up USA 0 USA 2.37 South Africa 0 Switzerland 8.45 India 80.24 Others 8.94

Cipla Ltd.

Cipla Ltd.

Financial

Business

SIGN UP FOR FREE